InterMune Company Profile (NASDAQ:ITMN)

About InterMune (NASDAQ:ITMN)

InterMune logoInterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ITMN
  • CUSIP: 45884X10
  • Web: N/A
Average Prices:
  • 200 Day Moving Avg: $68.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -55.56
  • P/E Growth: 0
  • Dividend Yield: 1.0%
Frequently Asked Questions for InterMune (NASDAQ:ITMN)

What is InterMune's stock symbol?

InterMune trades on the NASDAQ under the ticker symbol "ITMN."

Who are some of InterMune's key competitors?

How do I buy InterMune stock?

Shares of InterMune can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InterMune's stock price today?

One share of InterMune stock can currently be purchased for approximately $73.89.

MarketBeat Community Rating for InterMune (NASDAQ ITMN)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for InterMune (NASDAQ:ITMN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for InterMune (NASDAQ:ITMN)
No equities research coverage for this company has been tracked by


Earnings History for InterMune (NASDAQ:ITMN)
Earnings by Quarter for InterMune (NASDAQ:ITMN)
Earnings History by Quarter for InterMune (NASDAQ ITMN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2014Q214($0.56)($0.72)$33.96 million$35.70 millionViewListenView Earnings Details
5/1/2014Q114($0.62)($0.59)$28.24 million$30.30 millionViewListenView Earnings Details
7/24/2013Q2 2013($0.70)($0.77)$12.95 million$14.40 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.73)($0.64)$10.53 million$10.53 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.87)($0.90)$8.31 million$8.20 millionViewListenView Earnings Details
11/7/2012Q312($0.83)($0.70)$6.31 million$7.50 millionViewN/AView Earnings Details
7/23/2012$0.10$0.01ViewN/AView Earnings Details
4/26/2012($0.70)($0.74)ViewN/AView Earnings Details
2/9/2012($0.71)($0.69)ViewN/AView Earnings Details
11/3/2011($0.72)($0.63)ViewN/AView Earnings Details
8/4/2011($0.62)($0.68)ViewN/AView Earnings Details
4/28/2011($0.78)($0.57)ViewN/AView Earnings Details
2/16/2011$0.64$3.34ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for InterMune (NASDAQ:ITMN)
Current Year EPS Consensus Estimate: $-2.74 EPS
Next Year EPS Consensus Estimate: $-1.33 EPS


Dividend History for InterMune (NASDAQ:ITMN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for InterMune (NASDAQ:ITMN)
Insider Trades by Quarter for InterMune (NASDAQ:ITMN)
Insider Trades by Quarter for InterMune (NASDAQ:ITMN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2014Andrew Kenneth William PowellEVPSell7,500$73.47$551,025.00View SEC Filing  
8/13/2014Paul D ArataEVPSell7,500$50.00$375,000.00View SEC Filing  
8/11/2014John HodgmanCFOSell4,724$43.05$203,368.20View SEC Filing  
8/7/2014Daniel G WelchCEOSell171,025$44.98$7,692,704.50View SEC Filing  
7/17/2014Paul D ArataEVPSell2,382$41.00$97,662.00View SEC Filing  
7/15/2014Jonathan A LeffEVPSell35,000$43.08$1,507,800.00View SEC Filing  
6/18/2014Sean P NolanEVPSell10,000$47.10$471,000.00View SEC Filing  
6/16/2014Daniel G WelchCEOSell15,000$45.02$675,300.00View SEC Filing  
6/13/2014Sean P NolanEVPSell20,000$42.80$856,000.00View SEC Filing  
6/4/2014Daniel G WelchCEOSell3,914$39.19$153,389.66View SEC Filing  
6/3/2014John HodgmanCFOSell1,201$38.78$46,574.78View SEC Filing  
6/3/2014Jonathan A LeffEVPSell1,153$38.78$44,713.34View SEC Filing  
5/30/2014Daniel G WelchCEOSell4,565$40.06$182,873.90View SEC Filing  
5/29/2014David S KabakoffDirectorSell5,000$39.56$197,800.00View SEC Filing  
5/27/2014Daniel G WelchCEOSell41,493$40.03$1,660,964.79View SEC Filing  
5/19/2014Sean NolanEVPSell7,500$39.50$296,250.00View SEC Filing  
5/8/2014Sean NolanVPSell2,644$35.85$94,787.40View SEC Filing  
5/6/2014Daniel WelchCEOSell60,432$34.76$2,100,616.32View SEC Filing  
3/4/2014Jonathan LeffEVPSell27,361$30.95$846,822.95View SEC Filing  
3/4/2014Nepi Giacomo DiDirectorSell70,000$30.84$2,158,800.00View SEC Filing  
1/10/2014Daniel WelchCEOSell50,000$17.00$850,000.00View SEC Filing  
12/2/2013Daniel WelchCEOSell20,000$13.99$279,800.00View SEC Filing  
10/1/2013Daniel G WelchCEOSell70,000$15.43$1,080,100.00View SEC Filing  
8/30/2013David KabakoffDirectorSell10,002$14.82$148,229.64View SEC Filing  
8/27/2013Angus RussellDirectorBuy6,600$14.53$95,898.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for InterMune (NASDAQ:ITMN)
Latest Headlines for InterMune (NASDAQ:ITMN)
DateHeadline logoTop Analyst Upgrades and Downgrades: Foot Locker, CBOE, InterMune, US Steel and More - April 7 at 10:31 AM logo[video] Pisani: Ideal conditions for stock owners - April 7 at 10:31 AM logoMarkets Open Higher; Burger King In Talks To Buy Tim Hortons - April 7 at 10:31 AM logo[video] Jim Cramer Says Roche's "Bolt-On" Acquisition Means Big Pharma is Thinking Big - April 7 at 10:31 AM logo[video] Unusual Activity: InterMune - April 7 at 10:31 AM logoETFs for Hedge Funds’ Favorite Pharma Stocks - April 7 at 10:31 AM logoStocks End Higher; S&P 500 Pulls Back From 2,000 Level - April 7 at 10:31 AM logoSummer Rally Contiues on Lower Volume - April 7 at 10:31 AM logoInterMune (ITMN) Worth Watching: Stock Rises 35.4% - April 7 at 10:31 AM logoStock Market News for August 26, 2014 - April 7 at 10:31 AM logoRoche Furthers Immunotherapy Program with SP142 Launch - April 7 at 10:31 AM logoCelgene, Gilead Lead Big Biotech Stock Movers - April 7 at 10:31 AM logoMarkets Reverse Early Morning Losses; Still Lower On The Day - April 7 at 10:31 AM logoETF Performance Report: An August to Remember - April 7 at 10:31 AM logoWhen does the biotech party end? - April 7 at 10:31 AM logoEx-InterMune executive, friend found liable for insider trading - November 14 at 5:56 PM logoYour jet-black iPhone 7 might not look new for long - September 15 at 6:08 PM logoThe Push and Pull of Gender for Muslims at the Hajj - September 15 at 6:08 PM logoNetflix's 'White Helmets' Highlights a Syrian Rescue Group on the Front Line - September 15 at 6:08 PM logoIndians, Some Seeking Brighter Fortunes, Celebrate Vibrant Ganesh Festival - September 15 at 6:08 PM logoInterMune drug may offer big upside to Roche if aimed at liver - August 27 at 5:58 PM logoUS STOCKS-Futures point to higher open; S&P 500 near record - August 25 at 8:51 AM logoUS STOCKS-Futures rise on hopes for ECB action, merger activity - August 25 at 7:22 AM logoRoche to buy California biotech firm InterMune for $8.3 billion - August 24 at 7:29 PM logoInterMune taps banks as it braces for buyout bids -sources - August 13 at 1:13 PM



InterMune (ITMN) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by Staff